Follow Summit Therapeutics to never miss an important update.
On September 28, Summit agreed to sell 2 billion dollars worth of convertible preferred stock to a subsidiary of AstraZeneca. The deal is priced at about $18.36 per common share, which is higher than where the stock has been trading recently. This investment gives AstraZeneca certain rights if another company tries to buy Summit in the future.
This is a massive vote of confidence from one of the world's largest drugmakers. Summit is currently a clinical-stage company with no revenue, and this cash infusion more than triples its last reported cash pile. It provides the financial runway needed to launch its lead lung cancer drug, ivonescimab, and suggests that a major industry player sees the drug as a serious threat to the current standard of care.
Source: 8-K filing
Summit announced that data from a Phase III trial, the final stage of testing before seeking government approval, will be featured at the European Society for Medical Oncology congress in October. The study, conducted in China by Summit's partner Akeso, tested ivonescimab alongside chemotherapy in patients with cancer of the bile ducts.
This is a notable development because it shows the drug’s potential beyond lung cancer, which is its primary focus today. If ivonescimab can prove it works across multiple types of tumors, it significantly expands the number of patients the company can eventually treat. For long-term owners, these results will provide more evidence of whether the drug is truly a versatile tool that can compete with the world's current top-selling cancer treatments.
Source: Business Wire
Summit Redstone Partners established a target price of $25 for the stock. This is slightly below the average analyst target of $27, but it still suggests the stock could rise more than 40 percent from where it trades today. Price targets represent where an analyst thinks a stock will trade in the next year. While these numbers often change as new data comes in, this call reflects a general expectation that the company's value will grow as it moves closer to a regulatory decision for its lead lung cancer drug.
Source: Summit Redstone Partners
Summit's partner, Akeso, shared updated survival data from a large study in China comparing their drug, ivonescimab, to Merck's Keytruda. The results showed that ivonescimab provided a meaningful benefit in how long patients with a specific type of advanced lung cancer lived without their disease getting worse.
This is a key step for the company because Keytruda is currently the top-selling cancer drug in the world. Showing that ivonescimab can perform better in a direct comparison supports the idea that it could eventually take over a large part of that market. While this study was conducted in China, the results provide a strong foundation for the global trials currently underway.
Source: Business Wire
Jefferies upgraded the company from a hold to a buy rating on Wednesday. This change follows recent clinical data showing that Summit's lead drug, ivonescimab, performed better than Merck's Keytruda in a head-to-head lung cancer trial. Keytruda is currently the top-selling cancer drug in the world, and beating it in a trial is a rare and significant milestone for a smaller biotech firm.
While the average price target across all analysts sits at $27, this specific upgrade from a major firm reflects growing confidence that the drug could win regulatory approval. If the drug is approved by the FDA in November, Summit would move from a research-focused company with no revenue to a commercial player in the massive oncology market.
Summit has missed analyst profit targets in five of the last eight quarters. This suggests the business is still in a volatile stage where spending on drug trials is difficult to predict.
| Expectation | |
|---|---|
| EPS | $-0.28 |
| Revenue | $0M |
Follow Summit Therapeutics to get the latest and most important updates.
Follow SMMT